The intended selling valuation represents an increase of 47% from the valuation at the time of SciSparc's initial investment in MitoCareX Bio

Register to unlock this article

Register to read this story and more for free.

Signing up for an account helps us improve your browsing experience.

Continue

OR

See our subscription options.

Already have an account? Log in here